SL-0439

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameSL-0439
Drug Alias NameDual-targeting BCMA-GPRC5D CAR-T cell therapy (Beijing GoBroad Hospital)SL0439SL-0439
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsT lymphocyte replacementsG-protein coupled receptor family C group 5member D modulators
TargetsB-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Liquan HospitalBeijing GoBroad HospitalShanghai Rui Jin Hospital
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A